| Literature DB >> 33060363 |
Stephanie M Bester1, Guochao Wei1, Haiyan Zhao2, Daniel Adu-Ampratwum3, Naseer Iqbal2, Valentine V Courouble4, Ashwanth C Francis5, Arun S Annamalai1, Parmit K Singh6,7, Nikoloz Shkriabai1, Peter Van Blerkom2, James Morrison1, Eric M Poeschla1, Alan N Engelman6,7, Gregory B Melikyan5, Patrick R Griffin4, James R Fuchs3, Francisco J Asturias8, Mamuka Kvaratskhelia9.
Abstract
The potent HIV-1 capsid inhibitor GS-6207 is an investigational principal component of long-acting antiretroviral therapy. We found that GS-6207 inhibits HIV-1 by stabilizing and thereby preventing functional disassembly of the capsid shell in infected cells. X-ray crystallography, cryo-electron microscopy, and hydrogen-deuterium exchange experiments revealed that GS-6207 tightly binds two adjoining capsid subunits and promotes distal intra- and inter-hexamer interactions that stabilize the curved capsid lattice. In addition, GS-6207 interferes with capsid binding to the cellular HIV-1 cofactors Nup153 and CPSF6 that mediate viral nuclear import and direct integration into gene-rich regions of chromatin. These findings elucidate structural insights into the multimodal, potent antiviral activity of GS-6207 and provide a means for rationally developing second-generation therapies.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33060363 DOI: 10.1126/science.abb4808
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728